panitumumab,olaparib,nivolumab,ipilimumab,osimertinib,bevacizumab,apalutamide
takeda,bms,roche,merck,astrazeneca,amgen,janssen
['cairo5', 'adaura', 'gism', 'lcsm,(-blcsm)', 'gusm', 'niche2', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', '#gi', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'propel', 'nsclc', 'presto', 'sclc', 'crpc', 'aura ,(-laura)']
day 3 #esmo22 highlights #communityoncology 1. #cairo5 - unresec. crc w/ liver mets 2. #propel update - mcrpc 3. #presto - m0 hspc 4. #adaura update - adj nsclc 5. #niche2 - neoadj io in colon ca 1/6 #medtwitter #onced #gism #gusm #lcsm 
Practice changing #Oncology news from #CommunityOncologists perspective w/ Rohit Gosain @UPMCHillmanCC & Rahul Gosain @WilmotCancer. Views are our own.